AI assistant
Entera Bio Ltd. — Director's Dealing 2022
Nov 15, 2022
35604_dirs_2022-11-15_4e46a619-e7cb-471f-b709-1818acef619f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2022-11-11
Reporting Person: Yaacov-Garbeli Dana (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-11-11 | Ordinary Shares, par value NIS 0.0000769 per share | P | 30000 | $0.52 | Acquired | 30000 | Indirect |
| 2022-11-14 | Ordinary Shares, par value NIS 0.0000769 per share | P | 26580 | $0.536 | Acquired | 56580 | Indirect |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.50 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These shares are owned by A2Z Counseling Ltd. of which the Reporting Person's owns a 33.33% interest and has effective control over voting and disposition of the shares. The Reporting Person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.53 to $0.54, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.